RHH646

RHH646 is an investigational oral small molecule drug being developed for the treatment of knee osteoarthritis. It is designed to potentially regenerate articular cartilage in the knee, addressing a key underlying cause of osteoarthritis rather than just managing symptoms. The drug is currently in Phase 2 clinical trials, where its safety, tolerability, and efficacy—specifically its ability to repair or regenerate damaged cartilage—are being evaluated. The mechanism of action has not been publicly disclosed as of now. RHH646 is administered orally as a capsule once daily over a 12-month period in clinical studies[1][2][3][5][7].